1175. Tandem Heart-Associated Fevers: Does the Fever Signify Infection? Mustafa Hasan, MD; Sandhya Nagarakanti, MD; Eliahu Bishbug, MD; Newark Beth Israel Medical Center, Newark, New Jersey

**Session:** 142. HAI, Device-Associated: Vascular Devices **Friday, October 4, 2019: 12:15 PM**

**Background.** Tandem Heart (TH) is a percutaneously inserted ventricular assist device, unique device connects an extracorporeal axial flow pump to a catheter that crosses the atrial septum and aspirates blood from the left atrium which is returned to the femoral artery. TH is used as a bridge to transplantation or to another surgically inserted device. Fever was noted in patients after TH insertion. The objective of this study was to evaluate whether the fever after TH insertion is associated with an infection.

**Methods.** A retrospective review in a 680-bed tertiary care hospital from 2013 to 2016. Patients with TH were included. Data were collected on demographics, clinical presentation, onset and duration of fever, type of infections when present, and outcome. Student t-test was used for analysis.

**Results.** TH was inserted in 52 patients; males 41 (79%), mean age 56 years (range 25–80). Indication for TH was an acute exacerbation of congestive heart failure in 37/52 (71%) and cardiogenic shock with acute cardiomyopathy in 15/52 (29%). Mean duration of TH 9.4 days (Range: 1–29). Comorbidities were DM 19 (37%), hypertension 23 (44%), chronic kidney disease (CKD) 13 (25%), smoking 10 (19%). Fever within 72 hours of TH insertion was noted in 23/52 (44%), of these 6/23 (26%) had a documented infection. Pneumonia in 3, *Clostridium difficile* colitis 1, candida line infection 1 and 1 patient had both pneumonia and Enterobacter bacteremia. The fever lasted an average of 127 hours in patients with a documented infection vs. 45 hours in patients without a documented infection. 

**Conclusion.** In our patients with TH, fever was a prominent clinical feature; however, infection was seen in only a quarter of patients after TH insertion. Fever duration was significantly longer in patients with a documented infection and their device was present for a longer duration. The mortality was higher in patients with fever and infection. The reason for fever without a documented infection remains obscure and requires further investigation.

**Disclosures. All authors:** No reported disclosures.

1176. Antibiotic Prophylaxis Strategies Prior to Left Ventricular Assist Device Implantation: A Survey of Practice

Ahmad Mourad, MD; Muath Bishawi, MD, MPH; Sana Arif, MBBS; Rachel Miller, MD; Rachel Miller, MD; Stacey Maskariniec, MD, PHD; Duke University Medical Center, Durham, North Carolina; Duke University, Durham, North Carolina

**Session:** 142. HAI, Device-Associated: Vascular Devices **Friday, October 4, 2019: 12:15 PM**

**Background.** Short duration, single-agent antimicrobial prophylaxis with anti-staphylococcal activity is recommended at the time of left ventricular assist device (LVAD) placement to prevent infection-related complications. Despite consensus guidelines, there continues to be wide variability in antimicrobial regimens among implantation centers. The aim of this study was to characterize current peri-operative antimicrobial prophylactic strategies at different LVAD implantation centers.

**Methods.** A survey study was conducted from September 26, 2017 to October 25, 2017. Surveys were distributed electronically to both LVAD coordinators and infec-tious diseases specialists at 75 US medical centers identified as having an LVAD program. Data collection included information about antimicrobial selection, duration, MRSA screening and decolonization procedures.

**Results.** We received 29 survey responses. The majority of surveys were completed by infectious diseases physicians (72.4% (21/29)). Most responding centers reported LVAD programs established for >10 years (20/29 (69%). Cardiac transplant-ation was performed in 28/29 (96%) centers. Of centers reporting a defined anti-microbial prophylaxis regimen for nonpenicillin allergic patients [97% (28/29), 17.9% (5/28) reported a four-drug regimen, 35.7% (10/28) reported a three-drug regimen, and 46.4% (13/28) reported a two-drug regimen, while no centers reported a single-drug regimen. Empiric fluconazole was common [50% (14/28)] and 96.4% (27/28) and 46.4% (13/28) reported a two-drug regimen, while no centers reported a single-drug regimen. Empiric fluconazole was common [50% (14/28)] and 96.4% (27/28) and 46.4% (13/28) reported a two-drug regimen, while no centers reported a single-drug regimen.

**Conclusion.** Our survey results indicate a wide variation in the peri-operative antimicrobial prophylaxis regimens among participating LVAD centers. These results highlight the need for further studies evaluating the utility, toxicity, and stewardship implications of multi-drug regimens and whether specific clinical factors that prolong antimicrobial duration impact post-operative LVAD-related infection rates.

**Disclosures. All authors:** No reported disclosures.

1177. A Spectrum of Infectious Complications in Continuous-Flow Ventricular Assist Devices: A Single-Center Longitudinal Cohort

Scott C. Roberts, MD; Jonathan D. Rich, MD; Duc T. Pham, MD; Rebecca Harap, BSN; Valentina Stosor, MD; Fellow, Chicago, Illinois;

**Session:** 142. HAI, Device-Associated: Vascular Devices **Friday, October 4, 2019: 12:15 PM**

**Background.** Continuous flow ventricular assist devices have gained significant interest as a bridge to transplantation and destination therapy due to higher survival rates. Infectious complications (ICs) are frequent which can lead to higher mortality rates. There is a lack of prospective data evaluating different clinical settings. We aimed to identify the characteristics of patients with ICs in a single center with a comprehensive surveillance system.

**Methods.** We evaluated all continuous-flow ventricular assist devices from January 2013 to December 2018. Patients with TH were included. Data were collected on demographics, clinical presentation, onset and duration of fever, type of infections when present, and outcome. Student t-test was used for analysis.

**Results.** We received 29 survey responses. The majority of surveys were completed by infectious diseases physicians (72.4% (21/29)). Most responding centers reported LVAD programs established for >10 years (20/29 (69%). Cardiac transplant-ation was performed in 28/29 (96%) centers. Of centers reporting a defined anti-microbial prophylaxis regimen for nonpenicillin allergic patients [97% (28/29), 17.9% (5/28) reported a four-drug regimen, 35.7% (10/28) reported a three-drug regimen, and 46.4% (13/28) reported a two-drug regimen, while no centers reported a single-drug regimen. Empiric fluconazole was common [50% (14/28)] and 96.4% (27/28) and 46.4% (13/28) reported a two-drug regimen, while no centers reported a single-drug regimen. Empiric fluconazole was common [50% (14/28)] and 96.4% (27/28) and 46.4% (13/28) reported a two-drug regimen, while no centers reported a single-drug regimen.

**Conclusion.** Our survey results indicate a wide variation in the peri-operative antimicrobial prophylaxis regimens among participating LVAD centers. These results highlight the need for further studies evaluating the utility, toxicity, and stewardship implications of multi-drug regimens and whether specific clinical factors that prolong antimicrobial duration impact post-operative LVAD-related infection rates.

**Disclosures. All authors:** No reported disclosures.

**Figure:**

- **Central Line utilization rate per 1000 patient days**
  - 2016H1: 147.6
  - 2016H2: 152.3
  - 2017H1: 165.4
  - 2017H2: 139.9
  - 2018H1: 133.1
  - 2018H2: 155.2

- **Difference in Types of Line Infection from reported CLABSI**
  - Pre-Intervention: 2
  - Post-Intervention: 1

**Tables:**

- **Causative microorganism**
  - Gram Positive organism:
    - Coagulase Negative Staphylococci: 4
    - *S. aureus*: 8
    - Methicillin Sensitive: 0
    - Methicillin Resistant: 2
    - Enterococcus faecalis: 6
    - *V. welchii*: 1
    - Total: 20

- **Gram Negative organisms**
  - Escherichia coli: 3
  - Klebsiella Sp.: 1
  - Pseudomonas: 0
  - Other: 3
  - Total: 9

- **Fungi**
  - *Candida albicans*: 1
  - *Candida glabrata*: 1
  - *Candida parapsilosis*: 1
  - Other yeast: 1
  - Total: 5

**Disclosures. All authors:** No reported disclosures.
Background. Infections remain a frequent complication of patients (patients) with ventricular assist devices (VAD). We evaluated the epidemiology and outcomes of VAD infections at our center over a 10-year period.

Methods. We performed a retrospective cohort study of continuous-flow VAD recipients from July 2008-September 2018. VAD-specific and related infections were characterized according to the 2013 ISHLT definitions. Summary and comparative statistics were performed using IBM® SPSS Statistics version 25.0.

Results. 433 VADs were implanted into 375 patients. A total of 86 VAD infections occurred in 79 patients, with a mean incidence of 0.19 episodes/VAD and 0.20 episodes/pt. Patients with infections were predominantly male (73.3%) and Caucasian (54.6%), and had a mean age of 52.7 years, nonischemic cardiomyopathy (58.1%), and VAD as bridge to transplant (53.5%, n = 46). Types of VAD included 43.0% axial (n = 37) and 57.0% centrifugal flow (n = 49). 78% of patients with infections were colonized with at least one multidrug-resistant organism (MDRO) such as MRSA (29%), VRE (73%), and ESBL (24%).

Notably, 15% of infections (n = 13) occurred within 60 d of VAD implantation, with mean time to onset 338 d (69–1215 d). In late infections (>60d), impacted sites included skin (n = 2), 17.8% MDRO (n = 38), pocket (n = 7), and pump (n = 40), with 42 BSI, 36 IE, and 7 mediastinitis.

Conclusions. In this longitudinal retrospective cohort of patients supported with VADs, a majority of infections occurred >9 months post-implantation. GP pathogens predominated at all time-points. GN bacteria, including MDROs, anaerobes, and fungi are increasingly encountered. The vast majority of patients were colonized with 1 MDRO during the course of infection.

Disclosures. All authors: No reported disclosures.

1179. Rates and Causative Pathogens of Device-Associated Bloodstream and Urinary Tract Infections Attributed to Solid-Organ Transplant Units, 2015–2017
Nora Chea, MD and MSc; Liang Zhou, MStat; Shelley Magill, MD, PhD; Alice Gub, MD; Jonathan R. Edwards, MStat; Lauren Epstein, MD MSc; Matthew Sapiano, PhD; Center for Disease Control and Prevention, Atlanta, Georgia

Session: 142. HAI, Device-Associated: Vascular Devices
Friday, October 4, 2019: 12:15 PM

Background. Cardiovascular implantable electronic device (CIED) such as pacemaker (PPM) and automated implantable cardiac defibrillator (AICD) are commonly utilized in clinical practice. Definitions of device infection (DI) and guidelines for the work up and device extraction (DE) have been published by the American Heart Association and the Infectious Disease Society of America. Our objective was to evaluate whether the work up of DI as recommended was followed, and whether the device was extracted according to guidelines.

Methods. A retrospective review in a 680-bed tertiary care hospital. Adult patients (patients) >18 years who were diagnosed as having a DI and had the device extracted between 2008 and 2017 were included. Data were collected on demographic, device duration, blood culture (BC), echocardiogram utilization, lead cultures (LC) and device pocket cultures, appropriateness of extraction as per guidelines.

Results. Ninety-five patients were included. Mean age 68 years (range 23–90), 67 (71.1%) male. Devices included in 2013 ISHLT definition of device infections included: AICD in 75 (79%), PPM in 20 (21%). CHF was present <1 year prior to infection in 24(24%). Compliance with guidelines recommendation to draw blood cultures, obtain an echocardiogram and send lead cultures and device pocket cultures were seen in 100%, 90.5% and 49.4% and 67.7%, respectively. Criteria for extraction was met in 65/95 (69%), reason for extraction was a pocket infection in 16/65 (24.6%), bacteremia in 49/65 (75%), and invasive endocarditis in 38/65 (58%). Thirty (31.5%) had device extracted without meeting guidelines recommendation, in 17 a diagnosis of pocket infection but without microbiological criteria or clinical diagnosis. In 9 patients lead vegetation were seen but no cultures to support extraction. Mortality was seen in 4 patients, one during the extraction procedure.

Conclusion. In our institution, 1/3 of the patients diagnosed with DI had no indication for DE. Guidelines recommendation for CIED extraction should be followed as extraction could be associated with significant complications. In this study, overall compliance with guidelines work up recommendations were not consistently followed, especially LC and device pocket cultures.

Disclosures. All authors: No reported disclosures.

1178. Cardiac Device Infection: Do We Follow the Guidelines? Sandhya Nagarakanti, MD; Eliahu Bishburg, MD; Anita Bapat, MD; Newark Beth Israel Medical Center. Newark, New Jersey

Session: 142. HAI, Device-Associated: Vascular Devices
Friday, October 4, 2019: 12:15 PM

Background. Due to complex invasive medical procedures and compromised immunity, solid-organ transplant (SOT) patients are at high risk for infections. However, whether SOT patients are at higher risk than other hospitalized patients for selected healthcare-associated infections (HAI), such as central line-associated bloodstream infections (CLABSI) or catheter-associated urinary tract infections (CAUTI), or for infections with antimicrobial-resistant (AR) pathogens, is not well described. We analyzed data reported to the Centers for Disease Control and Prevention’s (CDC) National Healthcare Safety Network (NHSN) from inpatient SOT units and compared CLABSI and CAUTI rates and AR in hospitals with both SOT and non-SOT units.

Methods. We analyzed 2015–2017 CLABSI and CAUTI data reported to NHSN from hospitals with adult or pediatric inpatient SOT units. We calculated CLABSI and CAUTI incidence rates per 1,000 central-line days (CLD) and urinary catheter days (UCD), respectively, and compared rates, pathogen distributions, and AR among events attributed to three unit types: (1) SOT units; (2) adult, pediatric, and neonatal critical care units; and (3) adult and pediatric medical, surgical, and combined medical-surgical wards.

Results. CLABSI and CAUTI rates in SOT units were lower than rates in critical care units, but higher than rates in wards (table). Although the most common CLABSI and CAUTI pathogens were similar in all three unit types, the prevalence of individual pathogens differed (figure). Among CLABSI pathogens, Enterococcus faecium, Escherichia coli, and Klebsiella pneumoniae or oxytoca were significantly more prevalent in SOT compared with critical care units. Vancomycin resistance among CLABSI E. faecium was significantly lower (71.4% vs. 87.5%) and fluoroquinolone resistance among CAUTI E. coli was significantly higher (49.3% vs. 32.5%) in SOT compared with critical care units.

Conclusion. SOT units have lower CLABSI and CAUTI rates compared with critical care units. Differences in pathogens and AR among device-associated HAIs in SOT units should be considered when implementing infection prevention and treatment policies.

Table. CLABSI and CAUTI attributable to SOT units, NHSN, 2015–2017.

| CLABSI | CAUTI |
|-------|-------|
| SOT | CC units | Hours | SOT | CC units | Hours |
| No. infections | 41 | 41 | 41 | 42 | 42 |
| No. events | 180 | 2,453 | 1,275 | 224 | 2,943 | 986 |
| No. pathogens | 435 | 2,759 | 1,499 | 248 | 3,126 | 1,030 |
| No. device days | 392,953 | 1,536,241 | 1,381,369 | 180,758 | 1,922,367 | 830,164 |
| Incidence rate per 1,000 device days | 0.5 | 1.27 | 0.92 | 1.24 | 1.48 | 1.30 |

Figure. Top CLABSI and CAUTI pathogens in SOT units, critical care units, and wards.